Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine (MindMed) Inc. - Common Shares
(NQ:
MNMD
)
6.350
+0.040 (+0.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mind Medicine (MindMed) Inc. - Common Shares
< Previous
1
2
3
4
5
Next >
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
March 06, 2025
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Present at Leerink’s Global Healthcare Conference 2025
March 04, 2025
From
Mind Medicine Inc.
Via
Business Wire
Groups of Military Veterans Urge Congress to Expedite Research on Psychedelics
March 03, 2025
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
February 20, 2025
From
Mind Medicine Inc.
Via
Business Wire
New Study Shows Ibogaine Can Be Made Without Using Plant Matter
February 18, 2025
Via
Investor Brand Network
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
Mind Medicine Inc.
Via
Business Wire
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
January 30, 2025
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed to Be Added to the Nasdaq Biotechnology Index
December 19, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
December 16, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
December 11, 2024
From
Mind Medicine
Via
Business Wire
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
December 05, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
December 03, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Announces New Employee Inducement Grants
December 02, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
November 18, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed to Participate in Upcoming Investor Conferences
November 13, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
November 07, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
October 24, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Announces New Employee Inducement Grants
September 09, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Participate in September Investor Conferences
September 04, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
From
Mind Medicine Inc.
Via
Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
August 09, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
August 09, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 06, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
August 06, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
July 29, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
July 17, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
June 28, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 21, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
June 20, 2024
From
Mind Medicine
Via
Business Wire
MindMed to Participate in June Conferences
May 28, 2024
From
Mind Medicine Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.